Immunovaccine is conducting proof of concept and pre-clinical research for a number of potential infectious disease vaccines. Earlier studies have shown that the DepoVax™ platform is very well suited for development of effective single dose vaccine products because it is able to raise a much stronger antibody response than conventional vaccine formulations.
Immunovaccine is developing a vaccine against P. aeruginosa using a combination of our proprietary vaccine delivery technology called DepoVax™ and a mutated P. aeruginosa flagellin antigen. Immunovaccine’s DepoVax™ platform is a unique liposome in oil based technology which has been shown to significantly improve both humoral and CTL immune responses to weak antigens. The antigen being evaluated as an in-licensing opportunity has the potential to induce cross-protective immune responses. By combining a strong delivery technology and a good antigen, the company is developing a vaccine which will be able to stimulate a stronger immune response than previously observed with a flagellin-based vaccine, with a potential to protect from heterologous Pseudomonas strains. This product will have the potential to prevent and treat P. aeruginosa infections.
Immunovaccine has conducted successful pre-clinical studies to show capability to develop a DepoVax™ platform-based pandemic influenza vaccine for emergency stock-piling and use. Immunovaccine has demonstrated that a single dose of a DepoVax™-based vaccine can raise a significantly stronger response than two doses of the conventional formulation. The advantages of the DepoVax™ technology in this niche market include our single dose capability with protection in as little as two weeks and cross-protection potential. Lyophilization ensurs product stability for long term storage. This isessential since experts do not know exactly when a pandemic will occur.
Immunovaccine is evaluating possibilities to develop this vaccine further with a partner.
Immunovaccine has conducted successful proof of concept studies for development of a single dose Hepatitis B vaccine. The company combined well known Hepatitis B antigen with our unique DepoVax™ formulation. This patented combination has been shown by Immunovaccine to raise significantly stronger and long lasting humoral immune responses than conventional vaccines with a single dose in as little as one month. The company has a development plan for the Hepatitis B product.
With the involvement of a partner and appropriate financing, Immunovaccine could take the single dose Hepatitis B product forward into pre-clinical and clinical development in the relevant jurisdictions.